In lung cancer patients, tumor PD-L1 expression levels have attracted particular interest because NSCLC patients show higher expression levels and tend to respond more favorably to evolving PD-1 and PD-L1 inhibitors [5]. Here, CD274 is linked to lung carcinoma.